{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:39:49Z","timestamp":1781732389243,"version":"3.54.5"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI130186"],"award-info":[{"award-number":["R01AI130186"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p><jats:italic>Neisseria gonorrhoeae<\/jats:italic> has been classified by the U.S. Centers for Disease Control and Prevention as an urgent threat due to the rapid development of antibiotic resistance to currently available antibiotics. Therefore, there is an urgent need to find new antibiotics to treat gonococcal infections. In our previous study, the gold-containing drug auranofin demonstrated potent <jats:italic>in vitro<\/jats:italic> activity against clinical isolates of <jats:italic>N<\/jats:italic>. <jats:italic>gonorrhoeae<\/jats:italic>, including multidrug-resistant strains. Therefore, the aim of this study was to investigate the <jats:italic>in vivo<\/jats:italic> activity of auranofin against <jats:italic>N<\/jats:italic>. <jats:italic>gonorrhoeae<\/jats:italic> using a murine model of vaginal infection. A significant reduction in <jats:italic>N<\/jats:italic>. <jats:italic>gonorrhoeae<\/jats:italic> recovered from the vagina was observed for infected mice treated with auranofin compared to the vehicle over the course of treatment. Relative to the vehicle, after three and five days of treatment with auranofin, a 1.04 (91%) and 1.40 (96%) average log<jats:sub>10<\/jats:sub>-reduction of recovered <jats:italic>N<\/jats:italic>. <jats:italic>gonorrhoeae<\/jats:italic> was observed. In conclusion, auranofin has the potential to be further investigated as a novel, safe anti-gonococcal agent to help meet the urgent need for new antimicrobial agents for <jats:italic>N<\/jats:italic>. <jats:italic>gonorrhoeae<\/jats:italic> infection.<\/jats:p>","DOI":"10.1371\/journal.pone.0266764","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:33:35Z","timestamp":1650562415000},"page":"e0266764","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-4327","authenticated-orcid":true,"given":"Ahmed E. M.","family":"Elhassanny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader S.","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":true,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"pone.0266764.ref001","volume-title":"Sexually Transmitted Disease Surveillance","author":"Centers for Disease Control and Prevention","year":"2019"},{"issue":"8","key":"pone.0266764.ref002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"J Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"pone.0266764.ref003","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3389\/fimmu.2018.03187","article-title":"Human Immune Responses and the Natural History of Neisseria gonorrhoeae Infection","volume":"9","author":"A Lovett","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0266764.ref004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/MOH.0000000000000394","article-title":"Pathogenesis of Neisseria gonorrhoeae in the female reproductive tract: neutrophilic host response, sustained infection, and clinical sequelae","volume":"25","author":"JS Stevens","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"pone.0266764.ref005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.spid.2005.06.006","article-title":"Gonococcal infections in neonates and young children","volume":"16","author":"CR Woods","year":"2005","journal-title":"Semin Pediatr Infect Dis"},{"issue":"1","key":"pone.0266764.ref006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/sti.75.1.3","article-title":"From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection","volume":"75","author":"DT Fleming","year":"1999","journal-title":"Sex Transm Infect"},{"issue":"3","key":"pone.0266764.ref007","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"M Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"pone.0266764.ref008","article-title":"Sexually Transmitted Neisseria gonorrhoeae Infections-Update on Drug Treatment and Vaccine Development","volume":"8","author":"A Jefferson","year":"2021","journal-title":"Medicines (Basel)"},{"issue":"50","key":"pone.0266764.ref009","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC\u2019s Treatment Guidelines for Gonococcal Infection, 2020","volume":"69","author":"S St Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"49","key":"pone.0266764.ref010","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.15585\/mmwr.mm6949a5","article-title":"Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone","volume":"69","author":"MA Picker","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"pone.0266764.ref011","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.05760-11","article-title":"High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure","volume":"56","author":"M Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0266764.ref012","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"M Ohnishi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0266764.ref013","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/jac\/dks162","article-title":"Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain","volume":"67","author":"J Camara","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"pone.0266764.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States","author":"Centers for Disease Control and Prevention","year":"2019"},{"issue":"5","key":"pone.0266764.ref015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkab024","article-title":"High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018","volume":"76","author":"M Unemo","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"pone.0266764.ref016","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates","volume":"6","author":"PA Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"key":"pone.0266764.ref017","first-page":"62","article-title":"Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae","author":"NE Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0266764.ref018","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1038\/s41598-020-64352-2","article-title":"Auranofin Rapidly Eradicates Methicillin-resistant Staphylococcus aureus (MRSA) in an Infected Pressure Ulcer Mouse Model","volume":"10","author":"H Mohammad","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0266764.ref019","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1038\/s41598-021-86595-3","article-title":"In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection","volume":"11","author":"NS Abutaleb","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0266764.ref020","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1038\/s41598-020-64882-9","article-title":"Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection","volume":"10","author":"NS Abutaleb","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0266764.ref021","doi-asserted-by":"crossref","first-page":"105828","DOI":"10.1016\/j.ijantimicag.2019.10.009","article-title":"Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies","volume":"55","author":"NS Abutaleb","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"pone.0266764.ref022","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","article-title":"Antibacterial and antivirulence activities of auranofin against Clostridium difficile","volume":"53","author":"A AbdelKhalek","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"pone.0266764.ref023","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1038\/s41598-018-26674-0","article-title":"Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci","volume":"8","author":"A AbdelKhalek","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0266764.ref024","doi-asserted-by":"crossref","first-page":"22571","DOI":"10.1038\/srep22571","article-title":"Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens","volume":"6","author":"S Thangamani","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0266764.ref025","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/jac\/dkv163","article-title":"Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections","volume":"70","author":"L Aguinagalde","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"pone.0266764.ref026","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1073\/pnas.1504022112","article-title":"Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis","volume":"112","author":"MB Harbut","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0266764.ref027","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijantimicag.2015.12.016","article-title":"Repurposing auranofin for the treatment of cutaneous staphylococcal infections","volume":"47","author":"S Thangamani","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0266764.ref028","first-page":"67","article-title":"Long-term efficacy and safety of auranofin: a review of clinical experience","volume":"63","author":"RC Blodgett","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"issue":"3","key":"pone.0266764.ref029","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/apm.13014","article-title":"The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs","volume":"128","author":"S Foerster","year":"2020","journal-title":"APMIS"},{"issue":"1","key":"pone.0266764.ref030","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1038\/s41598-020-62696-3","article-title":"Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae","volume":"10","author":"A Elkashif","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0266764.ref031","article-title":"Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae","author":"M Alhashimi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0266764.ref032","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052427","article-title":"N-(1,3,4-Oxadiazol-2-yl)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae","volume":"22","author":"GA Naclerio","year":"2021","journal-title":"Int J Mol Sci."},{"key":"pone.0266764.ref033","article-title":"Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae","author":"CS Hewitt","year":"2021","journal-title":"ACS Infect Dis"},{"issue":"7","key":"pone.0266764.ref034","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02206-19","article-title":"Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae","volume":"64","author":"YJ Seong","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0266764.ref035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-4939-9496-0_24","article-title":"Female Mouse Model of Neisseria gonorrhoeae Infection","volume":"1997","author":"EL Raterman","year":"2019","journal-title":"Methods Mol Biol"},{"key":"pone.0266764.ref036","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmicb.2011.00107","article-title":"Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections","volume":"2","author":"AE Jerse","year":"2011","journal-title":"Front Microbiol"},{"issue":"12","key":"pone.0266764.ref037","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/infdis\/jis277","article-title":"Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations","volume":"205","author":"AN Kunz","year":"2012","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0266764.ref038","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2958.2008.06424.x","article-title":"Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness","volume":"70","author":"DM Warner","year":"2008","journal-title":"Mol Microbiol"},{"issue":"1","key":"pone.0266764.ref039","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/mi.2013.36","article-title":"Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells","volume":"7","author":"Y Liu","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"5","key":"pone.0266764.ref040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00325-18","article-title":"Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections","volume":"62","author":"MM Butler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0266764.ref041","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2016.06.009","article-title":"Antibacterial activity of resazurin-based compounds against Neisseria gonorrhoeae in vitro and in vivo","volume":"48","author":"DM Schmitt","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"pone.0266764.ref042","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/381125","article-title":"Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model","volume":"189","author":"SE Spencer","year":"2004","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0266764.ref043","doi-asserted-by":"crossref","first-page":"e1003559","DOI":"10.1371\/journal.ppat.1003559","article-title":"Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection","volume":"9","author":"S Gulati","year":"2013","journal-title":"PLoS Pathog"},{"issue":"6","key":"pone.0266764.ref044","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/mi.2017.11","article-title":"Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model","volume":"10","author":"Y Liu","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"4","key":"pone.0266764.ref045","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.4049\/jimmunol.1500292","article-title":"A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae","volume":"196","author":"J Shaughnessy","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"pone.0266764.ref046","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/iai.32.1.105-110.1981","article-title":"Gonococcal infection in endotoxin-resistant and endotoxin-susceptible mice","volume":"32","author":"PR Streeter","year":"1981","journal-title":"Infect Immun"},{"issue":"5","key":"pone.0266764.ref047","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0882-4010(90)90071-W","article-title":"Neisseria gonorrhoeae colonises the genital tract of oestradiol-treated germ-free female mice","volume":"9","author":"D Taylor-Robinson","year":"1990","journal-title":"Microb Pathog"},{"issue":"3","key":"pone.0266764.ref048","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/ard.35.3.251","article-title":"Auranofin. New oral gold compound for treatment of rheumatoid arthritis","volume":"35","author":"AE Finkelstein","year":"1976","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"pone.0266764.ref049","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/j.1875-9114.1983.tb03277.x","article-title":"Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis","volume":"3","author":"DE Furst","year":"1983","journal-title":"Pharmacotherapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:34:10Z","timestamp":1650562450000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266764"}},"subtitle":[],"editor":[{"given":"Joy","family":"Scaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266764","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}